HCV Inhibition Mediated Through the Nonstructural Protein 5A (NS5A) Replication Complex

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Annual Reports in Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-12-396492-2.00022-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

  2012cited by this paper
• Preliminary study of two antiviral agents for hepatitis C genotype 1.

  2012cited by this paper
• 845 PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS

  2012cited by this paper
• 1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

  2012cited by this paper
• A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

  2012cited by this paper
• 1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

  2012cited by this paper
• 1211 NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HCV GT-1 PATIENTS

  2012cited by this paper
• 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

  2012cited by this paper
• Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

  2012cited by this paper
• 1207 TRIPLE THERAPY WITH DACLATASVIR (DCV; BMS-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL

  2012cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE The Use of Liver Biopsy Evaluation in Discrimination of Idiopathic Autoimmune Hepatitis Versus Drug-Induced Liver Injury

  2011cited by this paper
• 1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• 1204 PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV NS5A INHIBITOR ABT-267 FOLLOWING SINGLE AND MULTIPLE DOSES IN HEALTHY ADULT VOLUNTEERS

  2011cited by this paper
• Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

  2011cited by this paper
• Telaprevir for retreatment of HCV infection.

  2011cited by this paper
• Regulation of the Production of Infectious Genotype 1a Hepatitis C Virus by NS5A Domain III

  2011cited by this paper
• Endogenous Histones Function as Alarmins in Sterile Inflammatory Liver Injury Through Toll-like Receptor 9 in Mice

  2011cited by this paper
• 764 IN VITRO PROFILING OF GSK2336805, A POTENT AND SELECTIVE INHIBITOR OF HCV NS5A

  2011cited by this paper
• Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

  2011cited by this paper
• Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

  2011cited by this paper
• TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

  2011cited by this paper
• Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures

  2011cited by this paper
• Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

  2010cited by this paper
• C. elegans SWAN-1 Binds to EGL-9 and Regulates HIF-1-Mediated Resistance to the Bacterial Pathogen Pseudomonas aeruginosa PAO1

  2010cited by this paper
• New Insights into Structure and Replication of the Hepatitis C Virus and Clinical Implications

  2010cited by this paper
• Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

  2010cited by this paper
• Development of novel therapies for hepatitis C.

  2010cited by this paper
• Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A.

  2010cited by this paper
• Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

  2009cited by this paper
• Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture.

  2009cited by this paper
• Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication

  2009cited by this paper
• Prevention of Cytotoxic T Cell Escape Using a Heteroclitic Subdominant Viral T Cell Determinant

  2008cited by this paper
• NS5A--from obscurity to new target for HCV therapy.

  2008cited by this paper
• Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

  2008cited by this paper
• Epidemiology of hepatitis C virus infection.

  2007cited by this paper
• Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.

  2006cited by this paper
• Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

  2005cited by this paper
• The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein*

  2004cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995cited by this paper

• Curious effects of fluorine on medicinally active compounds

  2021cites this paper
• Strategic Incorporation of Fluorine for Drug Discovery and Development

  2017cites this paper
• Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection

  2017cites this paper
• Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.

  2014cites this paper
• Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

  2014cites this paper
• Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.

  2014cites this paper
• Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.

  2014cites this paper
• Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

  2014cites this paper